This is a Phase 1b, multi-center, double-masked, randomized, placebo-controlled,
parallel-group study designed to evaluate the safety and biological activity of two doses of
EBI-005 ophthalmic solution versus placebo in subjects with moderate to severe Dry Eye
Syndrome. Approximately 72 subjects will be enrolled and randomized in this study at up to 9
centers located in the United States (US). Subjects will be enrolled in two groups or
cohorts. The first enrollment group will consist of 33 subjects.